Cullinan Therapeutics terminates exclusive MIT license for CLN-617; program abandoned

Cullinan Therapeutics, Inc.

Terminates Exclusive Patent License Agreement with MIT for CLN-617, effective Feb 18, 2026.
Decision based on not pursuing further development of CLN-617 cancer immunotherapy.
Company will return licensed patent rights for CLN-617 technology to MIT.
CLN-617 was an exclusive worldwide license for a cancer immunotherapy product.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.99

Cullinan Therapeutics, Inc. terminated Exclusive Patent License Agreement with Massachusetts Institute of Technology (MIT) valued at termination effective February 18, 2026; return of licensed patent rights for CLN-617 (effective 2026-02-18).

Action: termination
Agreement: license
Counterparty: Massachusetts Institute of Technology (MIT)
Value: termination effective February 18, 2026; return of licensed patent rights for CLN-617
Effective: 2026-02-18

Exact text from the filing

On November 18, 2025, in connection with its decision not to pursue further development of CLN-617, Cullinan Amber Corp. (the "Company"), a subsidiary of Cullinan Therapeutics, Inc. notified Massachusetts Institute of Technology ("MIT") of its decision to terminate the Exclusive Patent License Agreement, dated December 20, 2019 between the Company and MIT, as amended from time to time (the "License Agreement"), effective as of February 18, 2026.

View on SEC.gov

Browse all material agreements →

Cullinan Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-291448

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.